Baker Carrie N
Smith College.
J Health Polit Policy Law. 2023 Aug 1;48(4):485-510. doi: 10.1215/03616878-10449941.
This article examines the decades-long campaign to increase access to abortion pills in the United States, including advocates' work to win US Food and Drug Administration approval of mifepristone and misoprostol for abortion, the continuing restrictions on mifepristone, and the multiple strategies advocates have pursued to challenge these restrictions, including lobbying the FDA to remove the restrictions, obtaining a limited research exemption from FDA restrictions, and suing the FDA during the COVID-19 pandemic. The article pays particular attention to the influence of research conducted on the safety and efficacy of medication abortion as well as research on the impact of increased availability of abortion pills through telemedicine during the pandemic. The article also addresses self-managed abortion, wherein people obtain and use mifepristone and/or misoprostol outside the formal health care system, and it documents the growing network of organizations providing logistical, medical, and legal support to people self-managing abortion. The article concludes with reflections on the role abortion pills might play in the post-Roe era amid increasingly divergent abortion access trends across different regions of the United States.
本文审视了美国长达数十年的扩大堕胎药获取途径的运动,包括倡导者为使美国食品药品监督管理局(FDA)批准米非司酮和米索前列醇用于堕胎所做的工作、对米非司酮持续存在的限制,以及倡导者为挑战这些限制所采取的多种策略,包括游说FDA取消限制、获得FDA限制的有限研究豁免,以及在新冠疫情期间起诉FDA。本文特别关注关于药物流产安全性和有效性的研究影响,以及疫情期间通过远程医疗增加堕胎药可及性的影响研究。本文还探讨了自我管理堕胎,即人们在正规医疗系统之外获取和使用米非司酮和/或米索前列醇的情况,并记录了为自我管理堕胎者提供后勤、医疗和法律支持的组织网络不断扩大的情况。文章最后思考了在美国不同地区堕胎获取趋势日益分化的情况下,堕胎药在罗诉韦德案后的时代可能发挥的作用。